Advanced Cancer
Conditions
Keywords
cancer, atiprimod
Brief summary
The primary objectives of this study are to identify the maximum tolerated dose and to evaluate safety of atiprimod in patients with advanced cancer.
Detailed description
The primary objectives of this study are to identify the maximum tolerated dose(MTD) and to evaluate safety of atiprimod in patients with advanced cancer. The secondary objectives of this study are 1) to measure the pharmacokinetics of atiprimod and 2) to evaluate the efficacy of atiprimod treatment in patients with advanced cancers and 3) to compare the pharmacokinetics of atiprimod tablets and capsules at the starting dose, with the intent of switching to capsules for the dose escalation if the capsules pose no safety issues.
Interventions
DRUGAtiprimod
Sponsors
Callisto Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
13 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* histological proof of advanced cancer and must have failed or relapsed following standard therapy or have no standard therapy available. * estimated life expectancy of at least 12 weeks. * must have evaluable disease. * ECOG(Zubrod) PS of 0 to 2 * sign informed consent. * age 13 years or more at time of signing informed consent.
Exclusion criteria
* renal insufficiency * concomitant radiotherapy, chemotherapy or other investigational therapies. * peripheral neuropathy grade 3 or greater (NCI CTC version 3 grading) * evidence of clinically significant mucosal or internal bleeding * any condition that in the opinion of the investigator, places the patient at unacceptable risk if he/she were to participate in the study. * clinically relevant active infection or serious co-morbid medical conditions. * as atiprimod is a potent inhibitor of CYP2D6, patients taking drugs that are substrates of CYP2D6(e.g. beta blockers, antidepressants and antipsychotics will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objectives of this study are to identify the maximum tolerated dose | — |
| MTD) and to evaluate the safety of atiprimod when given in doses starting at | — |
| 60 mg/day and ranging to 360 mg/day, or the MTD, whichever is lower, in | — |
| patients with advanced cancer. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary objectives of this study are to measure the pharmacokinetics of | — |
| the dose escalation if the capsules pose no safety issues. | — |
| atiprimod, to evaluate the efficacy of atiprimod treatment in patients with | — |
| advanced cancer, and to compare the pharmacokinetics of atiprimod tablets and | — |
| capsules at the starting dose, with the intent of switching to capsules for | — |
Countries
United States
Outcome results
None listed